Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Living Well with Scleroderma

  |  Issue: March 2019  |  

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

  1. Alpiner N, Oh TH, Hinderer SR, Brander VA. Rehabilitation in joint and connective tissue diseases. 1. Systemic diseases. Arch Phys Med Rehabil. 1995 May;76(5 Spec No):S32–S40.
  2. Casale R, Buonocore M, Matucci-Cerinic M. Systemic sclerosis (scleroderma): An integrated challenge in rehabilitation. Arch Phys Med Rehabil. 1997 Jul;78(7):767–773.
  3. Poole JL. Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol. 2010 Mar;22(2):205–212.
  4. Willems LM, Vriezekolk JE, Schouffoer AA, et al. Effectiveness of nonpharmacologic interventions in systemic sclerosis: A systematic review. Arthritis Care Res. 2015 Oct;67(10):1426–1439.

Related Articles

    The 2022 ARP President’s & Merit Awards

    During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…